Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative versus postoperative SOX or CapeOX for locally advanced gastric cancer
ISRCTN12206108Phase 3Completed
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Sep 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin, tegafur and capecitabine in gastric adenocarcinoma (4 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Overall survival. Started Sep 2011; status: completed.
02
Drugs
oxaliplatintegafurcapecitabine
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on ISRCTN12206108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12206108.